Nuvation Bio Inc.
NUVBDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Oct 1, 2026
6wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
How NUVB's past catalysts played out
Taletrectinib
Non Small Cell Lung Cancer
Crizotinib
Non Small Cell Lung Cancer
safusidenib
Glioma
NUV-1511
Advanced Solid Tumor
AB-106
Non Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Taletrectinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
safusidenib | Phase 3 | Glioma | - | - |
NUV-1511 | Phase 2 | Advanced Solid Tumor | - | - |
AB-106 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Nuvation Bio Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Nuvation Bio Inc.'s (NUVB) pipeline across Phase 3, Phase 2. Its lead program is Taletrectinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nuvation Bio Inc.'s next FDA catalyst?→
Nuvation Bio Inc.'s (NUVB) next tracked catalyst is a PDUFA expected October 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NUVB biotech catalysts?→
Add NUVB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nuvation Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.